← Back to all trials
Active Not Recruiting
NCT06902857
Study on the Predictive Value of High-sensitivity Cardiac Troponin I, N-terminal Pro-B-natriuretic Peptide, and Soluble Suppression of Tumorigenesis-2 for Mortality and the Development of Cardiovascular Events in Patients With Type 2 Diabetes (Diabetes-CV)
Conditions: Type 2 Diabetes, Cardiovascular Complication
Sex: All
Ages: 50 Years – N/A
Enrollment: 964
Sponsor: Istituto Nazionale di Ricovero e Cura per Anziani
Location: IRCCS INRCA Hospital Ancona
Summary
The Diabetes-CV study is an observational study designed to assess the prognostic value of serum cardiac damage markers high-sensitivity cardiac troponin I (hs-cTnI), N-terminal pro-B-natriuretic peptide (NT-proBNP), and soluble suppression of tumorigenesis-2 (sST2) in predicting mortality, major adverse cardiovascular events, and diabetic complications in patients with type 2 diabetes.
Eligibility Criteria
Inclusion Criteria:
* type 2 diabetes
* patients attending the outpatient services
Exclusion Criteria:
* type 1 diabetes
* patients with active cancer or cancer in remission for less than 5 years
* any medical or other reason that leads the investigator to consider the subject ineligible for the study.
Source: ClinicalTrials.gov (NCT06902857). StuddyBuddy aggregates publicly available trial information.
